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A B S T R A C T
Combination approaches for the treatment of metabolic diseases such as obesity and diabetes are becoming
increasingly relevant. Co-administration of a glucagon-like peptide-1 receptor (GLP-1R) agonist with a chole-
cystokinin receptor-1 (CCKR1) agonist exert synergistic effects on weight loss in obese rodents. Here, we report
on the effects of a novel fusion peptide (C2816) comprised of a stabilized GLP-1R agonist, AC3174, and a CCKR1-
selective agonist, AC170222. C2816 was constructed such that AC3174 was linked to the N-terminus of
AC170222, thus preserving the C-terminal amide of the CCK moiety. In functional in vitro assays C2816 retained
full agonism at GLP-1R and CCKR1 at lower potency compared to parent molecules, whereas a previously re-
ported fusion peptide in the opposite orientation, (pGlu-Gln)-CCK-8/exendin-4, exhibited no activity at either
receptor. Acutely, in vivo, C2816 increased cFos in key central nuclei relevant to feeding behavior, and reduced
food intake in wildtype (WT), but less so in GLP-1R-deficient (GLP-1RKO), mice. In sub-chronic studies in diet-
induced obese (DIO) mice, C2816 exerted superior reduction in body weight compared to co-administration of
AC3174 and AC170222 albeit at a higher molar dose. These data suggest that the synergistic pharmacological
effects of GLP-1 and CCK pathways can be harnessed in a single therapeutic peptide.
1. Introduction
The prevalence of obesity and diabetes continues to rise across the
globe (Heal, Gosden, & Smith, 2013). As such, therapeutic agents tar-
geting multiple pathways are the most promising avenue to improve
efficacy (Finan, Clemmensen, & Muller, 2015; Tschop et al., 2016). For
example, combination approaches of small molecules (e.g., metformin,
DPP4 inhibitors, SGLT2 inhibitors, etc.) have been developed for dia-
betes (DeFronzo et al., 2016). However, there remains a need for other
combinatorial approaches that harness pharmacological synergies to
maximize benefits.
CCK is released from I-cells in the upper intestine and regulates food
intake via action at CCK-1 receptors (CCKR1s) (Noble et al., 1999).
While a small molecule CCKR1 agonist inhibited food intake, a lower
(more tolerable) dose did not significantly affect body weight in obese
humans (Jordan et al., 2008). GLP-1 is released from intestinal L-cells in
the more distal small intestine and colon in response to meals and
regulates glucose homeostasis (Campbell & Drucker, 2013). Modified
GLP-1 receptor (GLP-1R) agonists are commercially available for the
treatment of diabetes and obesity. We, and others, have previously
reported that CCK analogs and GLP-1R agonists interact to reduce body
weight in rodents (Irwin et al., 2013; Trevaskis et al., 2015). While CCK
and GLP-1 are able to exert synergistic effects on metabolism in rodents,
the clinical application of administering two separate peptides is chal-
lenging.
To overcome this, Irwin et al. created a single molecular entity by
linking a modified, stabilized version of CCK to a GLP-1R agonist
(Irwin, Pathak, & Flatt, 2015). This molecule, (pGlu-Gln)-CCK-8/ex-
endin-4, elicited metabolic improvements in DIO mice (Irwin et al.,
2015). The linear nature of this molecule, with the C-terminus of the
CCK moiety linked to the N-terminus of exenatide (abrogating the C-
terminal amide group from the CCK sequence necessary for activity)
appeared counter-intuitive for the retention of functional peptides of
these classes. Therefore, the aim of our studies was to generate and test
a fully functional dual-agonist fusion peptide utilizing the two peptide
sequences that we previously confirmed interact synergistically in
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rodents. The fusion peptide, C2816, comprised the GLP-1R agonist
peptide AC3174 linked to the CCKR1 agonist AC170222, with the C-
terminus of AC170222 free to be amidated. C2816, but not (pGlu-Gln)-
CCK-8/exendin-4, was determined to be a potent full agonist at both
CCKR1 and GLP-1R and to reduce body weight in DIO mice.
2. Materials and methods
2.1. Peptides
AC3174 (Amylin Pharmaceuticals) is a functional analog of exena-
tide (Hargrove et al., 2007). AC170222 (Hpa-Nle-Gly-Trp-Lys(Tac)-Asp-
NMePhe-NH2; CPC Scientific, Sunnyvale, CA) is a CCKR1-selective
peptide (Pierson et al., 2000). C2816 is a fusion peptide of AC3174
linked to AC170222 via a mini-PEG linker (His-Gly-Glu-Gly-Thr-Phe-
Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-
Glu-Trp-Leu-Lys-Asn-[PEG4]-Nle-Gly-Trp-Lys(Tac)-Asp-NMePhe-NH2);
New England Peptide, Gardner, MA). (pGlu-Gln)-CCK-8/exendin-4 was
synthesized by American Peptide Company (Sunnyvale, CA).
2.2. In vitro functional assays
Peptide activity at GLP-1R was determined by a cAMP accumulation
assay in Chinese hamster ovary (CHO) cells stably transfected with
human GLP-1 receptor (AstraZeneca), as described (Butler et al., 2015;
Naylor, Rossi, & Hornigold, 2016). Eleven-point duplicate concentra-
tion response curves were generated in 3 independent experiments and
data analysed as percent activation of the maximum GLP-1R ligand
response. Peptide activity at CCKR1 was measured using PathHunter®
eXpress CCKAR CHO-K1 β-arrestin recruitment assay from DiscoverX
(Fremont, CA, USA) as per manufacturer's guidelines.
2.3. Animal experiments
All studies were approved by the Institutional Animal Care and Use
Committee at MedImmune, LLC, in accordance with Guide for the Care
and Use of Laboratory Animals as adopted and promulgated by the U.S.
National Institutes of Health, or in accordance with the Animals
(Scientific Procedures) Act 1986 and approved by the local animal
ethics committees. All mice were housed individually in standard ca-
ging at 22 °C in a 12 h light:dark cycle.
2.4. Induction of cFos in mice
Male 8 week-old C57/BL6J mice (Charles River Laboratories,
Margate, UK) were fasted for 6 h, received an i.p. injection of saline
(n= 6) or C2816 (10 nmol/kg, n=6), anaesthetized 80min later with
pentobarbital sodium (100mg/kg, i.p.), and received a perfusion of
50mL of 0.01M PBS, followed by 50mL of 4% paraformaldehyde so-
lution prepared in KPBS (7.0% KHPO4, 1.4% KH2PO4, 8.8% NaCl).
Brains were post-fixed in 30% sucrose/4% paraformaldehyde at 4 °C.
Brain sections were treated with H2O2, then incubated in 5% normal
goat serum then a rabbit antibody raised against c-Fos (1:8000;
Cat#226 003, Synaptic Systems, Goettingen, Germany) followed by
standard secondary detection.
Table 1
Determination of peptide potency (EC50) at GLP-1 and CCK1 receptors ex-








GLP-1 (7-36amide) 3.5 ± 0.78 (7) NA (4)
CCK-8 NA (5) 4.6 ± 0.7 (7)
C2816 23.9 ± 18.0 (7) 298.0 ± 58.7 (5)
AC3174 3.0 ± 0.0.4 (7) NA (4)
AC170222 NT 18.2 ± 1.9 (4)
(pGlu-Gln)-CCK-8/exendin-4 99500 ± 10500 (4) NA (4)
Fig. 1. GLP-1:CCK fusion peptide C2816 is an ago-
nist at both GLP-1 and CCK receptors.
Concentration–response curves for peptide induced
increase in cAMP accumulation in CHO-hGLP-1R
cells (A) and increase in beta-arrestin recruitment in
CHO- hCCK-1R cells (B). Data shown are individual
data points (B) or mean (± SD) of duplicate (A)
fitted with 4-parameter logistic fit to determine EC50
and are representative of at least three independent
repeats.
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2.5. Acute food intake in wildtype and GLP-1R-deficient mice
Male wildtype (WT) and GLP-1R knockout mice (GLP-1RKO; 7–10
weeks of age; Jackson Laboratory, Bar Harbor, ME for MedImmune)
were randomized to 4 groups (n= 10/group): WT – vehicle, WT –
C2816, GLP-1RKO – vehicle, GLP-1RKO – C2816. On day−1 mice were
placed in a clean cage and fasted overnight. On day 0 mice were
weighed and dosed intraperitoneally (5mL/kg) with either vehicle
(PBS) or C2816 (50 nmol/kg) and pre-weighed amount of chow re-
turned to the cage. Food was weighed periodically for 24 h, and body
weight also measured at 24 h.
2.6. Pharmacology study in DIO mice
Obese male 10-week old C57BL6 mice (Jackson Laboratory) on
high-fat diet (D12492, 60% kcal/fat, Research Diets) were single
housed upon arrival and allowed to acclimate for 2 weeks. On day −3
mice were weighed and randomized to treatment groups (n=8/group)
based on body weight, with each mouse dosed once daily with two
compounds or vehicle administered separately. Mice were administered
vehicle/vehicle, AC3174 (7 nmol/kg)/vehicle, AC170222 (7 nmol/kg)/
vehicle, AC3174 (7 nmol/kg)/AC170222 (7 nmol/kg), C2816
(50 nmol/kg)/vehicle, or (pGlu-Gln)-CCK-8/exendin-4 (50 nmol/kg).
Drug was administered once daily for 10 days intraperitoneally (5 mL/
kg) 2 h prior to lights off. Body weight was measured daily; on day 10
mice had non-fasted blood glucose sampled from tail nick using a
glucometer (Breeze2 Ultra, Bayer), euthanized via CO2 inhalation and
cardiac blood collected for analysis of terminal lipids and plasma en-
zymes (Cobas c-111, Roche Diagnostics), and insulin (MSD, Rockville,
MD).
2.7. Kaolin intake in lean rats
Male Sprague Dawley outbred rats, aged ∼8 weeks (Envigo,
Frederick, MD) were maintained on chow diet (Envigo 2018 rodent
diet) and allowed to acclimate for at least 1 week. After the acclimation
period, rats were given chow and kaolin diet (K50001, Research Diets,
Billerica, MA) in adjacent separate compartments in a divided food
hopper. Rats were randomized to treatment groups based on 24 h chow
intake, 24 h kaolin intake and body weight (n=9/group). Following an
overnight fast in a clean cage, vehicle or C2816 (7 or 50 nmol/kg) was
administered intra-peritoneally. Cisplatin (10mg/kg; Sigma-Aldrich, St
Louis, MO) was administered i.p. as a positive control. Chow and kaolin
intake was recorded at 4 and 24 h. A final body weight was also re-
corded at 24 h.
2.8. Statistical analyses
Data were analyzed using one-way analysis of variance (ANOVA)
for single-point data comparing more than two groups, or two-way
ANOVA for longitudinal data. In both cases Tukey post hoc tests were
performed to determine statistically significant differences between
treatment groups. Significance was assumed for p < 0.05. Graphs and
statistical analyses were generated using Prism 6 for Windows
(Graphpad Software, San Diego, CA). For effect of C2816 on body
weight in wildtype and GLP-1R knockout mice and cFos analysis
Student's two-tailed t-test with Welch's correction was used, with a type
I error probability of p < 0.05 considered significant. All data are
expressed as mean ± SEM. A full statistical summary is presented in
Supplementary Table 1.
3. Results
3.1. In vitro activity of novel GLP-1:CCK fusion peptide C2816
Potency of C2816 was assessed in cellular assays reflecting agonist
activity at CCKR1 and GLP-1R relative to control peptides. Activity at
GLP-1R was assessed in cAMP accumulation assay in CHO-hGLP-1R
cells. C2816 acted as full agonist at hGLP-1R (Table 1, Fig. 1). C2816
was seven-fold less potent than AC3174 with EC50 23.9 ± 18.0 and
3.0 ± 4.0 pM, respectively. Activity at CCKR1 was assessed in β-ar-
restin recruitment assay in CHO-CCK1R cells. C2816 was a full agonist
with potency 16-fold weaker than AC170222 with EC50 of 18.1 ± 1.9,
4.6 ± 0.7 and 298.0 ± 58.7 nM for AC17022, CCK-8 and C2816 re-
spectively (Table 1, Fig. 1). The fusion peptide (pGlu-Gln)-CCK-8/ex-
endin-4 was inactive in CCKR1 and was a partial agonist> 30,000-fold
less potent than AC3174 in the GLP-1R assays with EC50
99.5 ± 10.5 nM (Table 1).
3.2. Acute food intake in wildtype and GLP-1R-deficient (GLP-1RKO) mice
To further confirm that the CCK portion of C2816 was biologically
active we performed an acute food intake assessment in WT and GLP-
1RKO mice. In overnight fasted WT mice, C2816 (10 nmol/kg) in-
hibited food intake relative to vehicle controls such that total 24 h food
intake was suppressed by 45% (p < 0.001; Fig. 2A). Inhibition of food
intake by C2816 was associated with a significant reduction in body
weight (Fig. 2B). In GLP-1RKO mice treated with C2816, 24 h food
intake was only suppressed by 7% relative to vehicle-treated GLP-1RKO
mice (p < 0.001; Fig. 2A), and body weight was not affected (Fig. 2B).
Fig. 2. GLP-1:CCK fusion peptide C2816 reduces food intake acute in wildtype
(WT) mice to a greater extent than GLP-1R-deficient (GLP-1RKO) mice, sug-
gesting that the CCK portion of C2816 is biologically active. (A) 24 h food in-
take and (B) change in body weight of overnight-fasted WT or GLP-1RKO mice
after a single administration of vehicle or C2816 (50 nmol/kg). *p < 0.05 vs.
vehicle (within genotype).
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3.3. C2816 activates central nuclei of the brain relevant to regulation of
food intake and body weight
We then explored whether C2816 activated regions previously im-
plicated in the anorectic response to GLP-1 and CCK signaling. We ex-
amined cFos immunoreactivity 80min following a single administra-
tion of C2816 or saline in the ventromedial, dorsomedial and
paraventricular nuclei of the hypothalamus (VMH, DMH, PVH) and the
nucleus tract of the solitarius (NTS) and the area postrema (AP) in the
caudomedial brainstem (Blevins, Stanley, & Reidelberger, 2000;
Rinaman, 2010; Secher et al., 2014). At the 10 nmol/kg dose tested
C2816 significantly increased cFos signal in the VMH, DMH and PVH
relative to saline controls (Fig. 3). In the brainstem, C2816 also in-
creased cFos in the NTS (Fig. 3) but not the AP (Fig. 3).
3.4. Sustained administration of C2816 reduces body weight in DIO mice
Administration of AC170222 to DIO mice did not affect body
weight, whereas AC3174 induced significant (−7.4%) body weight loss
(Fig. 4A). Co-administration of AC3174 and AC170222 further en-
hanced weight loss (−12.8%) relative to AC3174 alone (Fig. 4A).
C2816 profoundly reduced body weight by−28.4% vs. vehicle and was
significantly lower than all other groups (Fig. 4A). In agreement with in
vitro data, (pGlu-Gln)-CCK-8/exendin-4 was ineffective. C2816 reduced
epididymal fat and liver weight (Fig. 4B-C), however liver lipid content
was not altered (Fig. 4D). Blood glucose, plasma triglycerides and
cholesterol were reduced in C2816 group vs. all other groups and in-
sulin tended to be lower (Table 2). Plasma ALT was elevated in C2816
vs. AC3174, and AST and plasma lipase was higher in C2816 group vs.
all other groups (Table 2). Amylase was higher in C2816 mice relative
to AC3174 and (pGlu-Gln)-CCK-8/exendin-4 groups (Table 2).
3.5. C2816 does not induce pica in lean rats
We assessed the potential for C2816 to induce nausea/malaise in
rodents via determination of kaolin intake following acute adminis-
tration after an overnight fast in lean rats. Food intake was significantly
reduced by C2816 in a dose-dependent manner after single injection vs.
vehicle controls at 4 h and 24 h post-dose (Fig. 5A, C). Inhibition of food
intake corresponded with a reduction in overall body weight (Fig. 5E).
Neither dose of C2816 was associated with increased kaolin intake
(Fig. 5B, D), while administration of cisplatin which similarly reduced
food intake as high dose C2816 did increase 24 h kaolin consumption
(Fig. 5D).
4. Discussion
To harness two distinct pathways for the treatment of metabolic
disorders we generated a fusion peptide linking two peptides previously
validated as exerting synergistic benefits on body weight (Trevaskis
et al., 2015). The concept of a CCK:GLP-1 fusion peptide has been
previously explored (Irwin et al., 2015). Our molecule is conceptually
similar but in the opposite orientation (GLP-1:CCK), in order to retain
the free C-terminal amide group on the CCK moiety. Further, mod-
ifications of the N-terminus of GLP-1/exenatide typically impair func-
tion (Gallwitz et al., 1994). Thus, a GLP-1:CCK fusion peptide, which
we termed C2816, was generated. In vitro characterization revealed that
C2816 retained full agonist activity at both human CCKR1 and GLP-1R,
with slightly reduced potency. Biological activity of the CCK moiety of
C2816 was demonstrated by acute feeding studies in GLP-1RKO mice,
where a small but statistically significant effect of C2816 was observed,
suggesting some biological effect of the CCK portion of C2816. The
clear reduction in efficacy of C2816 in GLP-1RKO mice suggests a heavy
Fig. 3. Hypothalamic and brainstem neurons in mice are acutely activated by C2816. cFos immunoreactivity in the dorsomedial, venromedial and paraventricular
hypothalamic nuclei (DMH, VMH and PVH, respectively), and the nucleus tractus solitarius (NTS) and area postrema (AP) of the brainstem was quantitated 80min
following single injection of saline or C2816 (10 nmol/kg) to lean C57BL6J mice. Representative images of saline- and C2816-treated hypothalamic areas and
brainstem regions are shown.
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reliance on GLP-1R however caution should be taken. The ability of
C2816 to inhibit food intake in WT mice reflects not just engagement
with each receptor specifically, but also the synergistic component.
That is, at certain dose levels where CCK and GLP-1 exert synergistic
effects, studies in single receptor knockout mice may not fully capture
the contribution of each receptor to the overall sum effect. To date, such
detailed food intake studies have not been performed. Furthermore, to
gain a fuller understanding of the contribution of each part of C2816
similar studies in mice lacking CCKR1 would be necessary. Without an
equivalent food intake assessment in CCKR1-deficient mice to de-
termine the sole contribution of GLP-1R (without synergy) the question
as to whether C2816 is able to harness synergy or merely capture
partial activity of the parent molecules remains unanswered.
In a sustained dosing study in DIO mice C2816 exerted greater
weight loss relative to co-administration of the parent molecules,
however some experimental conditions need to be considered. Firstly,
the doses of the parent molecules used was less than C2816 on a molar
ratio. We anchored our dose strategy around a maximally effective dose
(∼30 μg/kg or 7 nmol/kg) of AC3174 (Hargrove et al., 2007). The dose
of C2816 was adjusted for the reduced potency at GLP-1R (7-fold),
leading to a final dose selection of 50 nmol/kg for C2816. Thus, if all
the biological effects of C2816 were mediated via GLP-1R then the ef-
ficacy would be similar between C2816 and the AC3174 treatment arm.
Secondly, the pharmacokinetic profiles and/or tissue distribution may
be different between C2816 and parent molecules. Finally, full activity
profiles at mouse receptors remains unknown and may diverge from
human receptor assays. With these caveats, C2816 exerted substantially
greater weight loss compared to co-administration of parent molecules
supporting the notion that activation of CCKR1 is a major contributor to
the overall efficacy of C2816. The nature of C2816-mediated weight
loss remains to be fully characterized, however it is likely that the
weight loss is, at least in part, mediated via central effects given the
Fig. 4. Sustained administration of C2816 induces body weight loss and metabolic improvements in DIO C57BL6 mice, superior to co-infusion of CCKR1 agonist
peptide (AC170222) and GLP-1 analog (AC3174) parent molecules. *p < 0.05 vs. vehicle, ˆp < 0.05 vs. AC3174, +p < 0.05 vs. AC170222, #p < 0.05 vs. (pGlu-
Gln)-CCK-8/exendin-4, ap<0.05 for C2816 group vs. all other groups at all study days, bp < 0.05 for AC3174 vs. vehicle, AC170222 and (pGlu-Gln)-CCK-8/
exendin-4 groups at all study days, cp < 0.05 vs. all other groups.
Table 2
Terminal blood glucose, and plasma concentrations of liver enzymes, lipids and exocrine pancreatic enzymes in diet-induced obese mice following 10 days of
treatment with vehicle, AC3174, AC17022, combination of AC3174 + AC170222, fusion peptide C2816, or (pGlu-Gln)-CCK-8/exendin-4. *p < 0.05 vs. vehicle,
ˆp < 0.05 vs. AC3174, +p < 0.05 vs. AC170222, #p < 0.05 vs. AC3174 + AC170222; †p < 0.05 vs. (pGlu-Gln)-CCK-8/exendin-4.
Vehicle AC3174 AC170222 AC3174 + AC170222 C2816 (pGlu-Gln)-CCK-8/exendin-4
Glucose (mg/dL) 298 ± 15 266 ± 15 280 ± 11 260 ± 12 183 ± 9*ˆ+#† 314 ± 11#
Insulin (ng/mL) 14.3 ± 5.2 6.4 ± 0.7 11.3 ± 4.1 5.0 ± 0.5 2.1 ± 0.8 13.8 ± 4.8
ALT (U/L) 56 ± 7 57 ± 15 86 ± 32 53 ± 6 132 ± 27# 56 ± 11
AST (U/L) 79 ± 11 71 ± 11 95 ± 27 67 ± 6 204 ± 52*ˆ+#† 81 ± 10
Cholesterol (mg/dL) 213 ± 6 219 ± 13 192 ± 28 164 ± 15 73 ± 17*ˆ+#† 192 ± 19
Triglycerides (mg/dL) 112 ± 10 108 ± 7 114 ± 6 94 ± 8 73 ± 7*ˆ+† 118 ± 11
Amylase (U/L) 2667 ± 94 2795 ± 83 2759 ± 75 2516 ± 131 2275 ± 171ˆ† 2858 ± 115
Lipase (U/L) 25 ± 1 50 ± 13 77 ± 49 118 ± 77 373 ± 103*ˆ+#† 46 ± 17
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cFos signal generated by C2816 in brain regions relevant to energy
balance regulation. These effects also appear to be independent of
malaise-inducing or emetic responses as C2816 failed to induce kaolin
intake in lean rats at doses that significantly reduced food intake and
body weight. The lack of pica behavior following C2816 administration
is in line with previous observations showing similar lack of kaolin
intake in rats treated with AC3174 in combination with several doses of
CCK8 (Trevaskis et al., 2015). Overall, the data show that the weight-
reducing effects of C2816 may be mediated centrally and independently
of malaise/nausea. Effects on other aspects of energy balance such as
energy expenditure or physical activity remain to be determined.
The mechanism/s of GLP-1 and CCK that can be harnessed phar-
macologically to induce synergistic effects on metabolism is/are un-
known. The key question that remains is: what is the minimal level of
CCKR1 agonism that can be safely used in conjunction with a GLP-1
that induces synergy, and could such a potency ratio be harnessed in a
single peptide? We demonstrated that full agonism of each receptor is
possible with a single peptide and it is likely that other molecules with
exquisite potency ratios can be generated. Further, the orientation of
such peptides is also important. It is clear that C2816, with the GLP-1-
to-CCK orientation, retained largely full biological effects whereas the
(pGlu-Gln)-CCK-8/exendin-4 molecule with the opposite CCK-to-GLP-1
orientation did not, exhibiting only partial GLP-1R agonism. As such,
the (pGlu-Gln)-CCK8/exendin-4 molecule, in our hands, did not elicit
any biological activity. Without more definitive analysis of compound
exposure or in vivo target engagement we cannot explain the dis-
crepancy between our observations and the reported efficacy of (pGlu-
Gln)-CCK8/exendin-4. The optimal orientation (and subsequent im-
plications on specific modulation of N- and C-terminal modifications to
the peptides and resultant disruption in potency and biological activity
as mentioned previously) and potency ratios of GLP-1:CCK fusion
peptides beyond that exemplified by C2816 will be required to explore
the question of the minimally effective contribution of CCKR1 agonism
to enhance GLP-1R pharmacotherapy in future studies.
In conclusion we generated a dual agonist fusion peptide, C2816,
harnessing both GLP-1R and CCKR1 pathways to induce significant
reductions in weight in obese mice. This molecule represents a pre-
liminary foray into GLP-1:CCK fusion peptides, highlighting the po-
tential utility of this approach as an example of combination therapy to
treat metabolic disease.
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